Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen

Nobuhiko Nakamura, Naoe Goto, Hisashi Tsurumi, Masao Takemura, Nobuhiro Kanemura, Senji Kasahara, Takeshi Hara, Ichiro Yasuda, Masahito Shimizu, Michio Sawada, Toshiki Yamada, Mitsuru Seishima, Tsuyoshi Takami, Hisataka Moriwaki

研究成果: Article査読

11 被引用数 (Scopus)

抄録

Background: Serum soluble tumor necrosis factor receptor 2 (sTNFR2) concentration predicted the clinical outcome of patients with aggressive non-Hodgkin's lymphoma including diffuse large B-cell lymphoma (DLBCL) treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) in our previous study. However, after rituximab (R) was introduced in clinical practice, R-CHOP replaced CHOP as the standard therapy for DLBCL. Patients and methods: In this study, we re-evaluated the prognostic significance of serum sTNFR2 in 154 patients with DLBCL treated with R-CHOP. Results: Five-yr overall survival (5-yr OS) rates with sTNFR2 ≥20 ng/mL and <20 ng/mL were 29.2% and 83.3% (P < 0.0001), respectively, and the corresponding 5-yr progression-free survival (5-yr PFS) rates were 26.9% and 76.4% (P < 0.0001), respectively. A multivariate analysis revealed that serum sTNFR2 and complete remission (CR) were independent prognostic factors for both OS (CR: P < 0.0001, sTNFR2: P = 0.0001) and PFS (CR: P < 0.0001, sTNFR2: P = 0.0001). The prognosis of patients with poor risk groups according to the revised International Prognostic Index who also had high serum sTNFR2 was especially poor. Conclusion: Serum sTNFR2 might be a powerful prognostic factor for patients with DLBCL in the rituximab era.

本文言語English
ページ(範囲)322-331
ページ数10
ジャーナルEuropean Journal of Haematology
91
4
DOI
出版ステータスPublished - 10-2013
外部発表はい

All Science Journal Classification (ASJC) codes

  • 血液学

フィンガープリント

「Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル